Stefan Gutow, MD
Urology · Albuquerque, NMNPI 1386691772
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Medtronic at 53.1% of the total. Reporting peaked in 2024 at $2,878 and has fallen 67.5% since, to $936 in 2025.
Across 90 payments — averaging $57.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Calyxo, Inc.$673
- Dornier Medtech America, Inc$422
- Astellas Pharma US Inc$304
- 180 Medical, Inc.$156
- Ferring Pharmaceuticals Inc.$91
- plus $800 from 21 others
What the payments were for
- Consulting fees$3507%
- Speaking & faculty fees$2,50048%
- Food & beverage$2,36245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 12 | $2,767 |
| Calyxo, Inc. | 8 | $673 |
| Dornier Medtech America, Inc | 1 | $422 |
| Astellas Pharma US Inc | 14 | $304 |
| 180 Medical, Inc. | 6 | $156 |
| Ferring Pharmaceuticals Inc. | 5 | $91 |
| Urogen Pharma, Inc. | 5 | $87 |
| Axonics, Inc. | 5 | $86 |
| Amgen | 5 | $84 |
| Johnson & Johnson | 3 | $58 |
| Sanofi | 3 | $58 |
| Boston Scientific | 3 | $53 |
| Bayer | 3 | $51 |
| Progenics Pharmaceuticals, Inc. | 3 | $50 |
| Pfizer | 2 | $31 |
| Novartis | 1 | $29 |
| Smith+Nephew | 1 | $26 |
| Conmed Corporation | 1 | $25 |
| Procept Biorobotics Corporation | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $21 |
| Teleflex LLC | 1 | $18 |
| Ambu Inc. | 1 | $17 |
| Covidien LP | 1 | $17 |
| Myovant Sciences Inc. | 1 | $16 |
| Immunitybio, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,603
- Dornier MedTech$422
- CVAC$350
- CVAC Aspiration System$141
How this compares
$5,212 in reported general payments places this provider in the 80th percentile of 46 urology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 190 | $121,166 |
| Tamsulosin Hcl | 685 | $15,247 |
| Finasteride | 410 | $7,236 |
| Terazosin Hcl | 86 | $3,137 |
| Solifenacin Succinate | 104 | $2,438 |
| Silodosin | 37 | $1,637 |
| Potassium Citrate ErPotassium Citrate | 20 | $1,354 |
| Dutasteride | 27 | $642 |
| Trimethoprim | 11 | $626 |
| Doxazosin Mesylate | 28 | $440 |
| Ciprofloxacin Hcl | 50 | $278 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $265 |
| Oxybutynin Chloride | 27 | $235 |
| Cephalexin | 26 | $225 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $304 | $121,166190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 urology providers in New Mexico.
Other urology in Albuquerque
- Wayne KuangAlbuquerque$128K
- Jordan ForemanAlbuquerque$60K
- Andrew GrollmanAlbuquerque$16K
- Aaron GeswaldoAlbuquerque$11K
- Jonathan NelsonAlbuquerque$6K
- Ron Ron ChengAlbuquerque$3K
- Frances AlbaAlbuquerque$3K
- Christopher SlaydenAlbuquerque$2K
- Frederick SnoyAlbuquerque$2K
- Damara KaplanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.